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Purpose
As a component of the Study of Integrative Medicine
Treatment Approaches to Chronic Pain (SIMTAP), we
examined the utilization and efficacy of these approaches
in a subset of patients with headache disorders. Specifi-
cally, we evaluated the ability to reduce headache disability
and predictors of treatment response.
Methods
The SIMTAP enrolled 142 subjects with headaches at 9
clinical sites between May, 2009 and October, 2010.
A subset of these subjects (N=38), who suffered with
headache disorders referred to one clinical site by a neu-
rologist, were further analyzed. In addition to baseline
demographics and treatment history, subjects had eva-
luation of hs-CRP, Vitamin D, BPI, and MIDAS at base-
line, 6, 12 and 24 weeks.
Results
At baseline, 55.2% had insufficient Vitamin D levels (<30
ng/mL) and 68.4% had an hsCRP level >1 mg/l. Mean
baseline MIDAS score was 46 (SD=43) with 89% categor-
ized as III or IV, meeting criteria for moderate to severe
disability. The most common treatments attempted were
biofeedback, acupuncture and manual therapy. 44.7% and
31.6% of subjects were able to reduce their MIDAS level
by one or two categories. BMI, hsCRP or serum Vitamin
D level at baseline did not predict improvement in head-
ache disability.
Conclusion
Headache sufferers evaluated at an integrative medicine
facility appear to have a significant burden of disease
based on baseline MIDAS scores, as well as characteris-
tics which may be related to their headaches, including
elevated CRP and insufficient Vitamin D levels, which
did not appear to predict improvement in this prelimin-
ary analysis. Individualized integrative medicine treat-
ment approaches were not associated with significant
decreases in mean MIDAS scores at 12 and 24 weeks,
but 44.7% of subjects reduced their headache burden by
at least one category. Further research is needed to bet-
ter understand clinical response to integrative medicine
approaches for headache and identifying predictors of
response.
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